Trials / Recruiting
RecruitingNCT04095156
Autoreactive B Cells in Membranous Nephropathy
PLA2R Autoreactive B-Cell Subsets and Immune Cell Monitoring in Membranous Nephropathy: Identification of Outcome Predictors and Novel Insights Into Disease Pathogenesis
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 86 (estimated)
- Sponsor
- Mario Negri Institute for Pharmacological Research · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
Membranous nephropathy (MN) is the most frequent cause of nephrotic syndrome (NS) in adults. The majority of MN patients show detectable circulating antibodies against the M-type phospholipase A2 receptor (PLA2R). Infusion of anti-CD20 monoclonal antibodies results in a profound depletion of B-cells, which are thought to be responsible for anti-PLA2R production. B-cell depletion is followed by NS remission in 70% of cases. Limited evidence highlighted that differences in the B- and T-cell compartments may exist between responders and non-responders. Owing to the non-homogenous efficacy of anti-CD20 treatment, investigators hypothesize that in MN patients who experience NS remission after B-cell depleting therapy, autoreactive B-cells may be mostly circulating, whereas in patients who do not respond to the same treatment, autoreactive B-cells may chiefly reside into secondary lymphoid organs - and thus be more resistant to the drug action. Researchers will therefore extensively analyze the circulating immune repertoire of MN patients before and after the infusion of B-cell lineage depleting agents, assessing the presence of circulating PLA2R autoreactive B cells from appropriately stratified responder and non-responder patients. Patients and healthy controls will be enrolled in this study. Patients will be stratified according to gender, anti-PLA2R status, type of B-cell lineage depleting agent received and response to treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | In vitro assays. | Biochemical and flow-cytometry analysis of specimen collected. |
Timeline
- Start date
- 2019-09-25
- Primary completion
- 2026-11-01
- Completion
- 2026-11-01
- First posted
- 2019-09-19
- Last updated
- 2026-03-20
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT04095156. Inclusion in this directory is not an endorsement.